On August 25, 2021, DiCE Molecules, a biopharmaceutical company leveraging its proprietary DNA-encoded library platform to discover and develop next-generation therapeutics in immunology and other therapeutic areas, filed for a customary $100 million IPO with the SEC, a day after it had announced the completion of its $60 million Series C-1 financing, which was led by RA Capital Management and Sands Capital, with participation from new and existing investors. Proceeds will support DiCE's lead program to build a pipeline of novel oral candidates to treat chronic diseases in immunology and other therapeutic areas.

The San Francisco, California-based company plans to list on the Nasdaq under the symbol "DICE." No pricing terms were disclosed.

The Wilson Sonsini Goodrich & Rosati team advising DiCE on patent matters related to both transactions includes Julia Minitti, Michael Hostetler, Ying Chen, and Luis Perla.

For more information, please see DiCE's press release on the Series C-1 financing. Visit Renaissance Capital and Fierce Biotech for coverage on the IPO.